Repligen appoints Maggie A. Pax to Board of Directors, expanding to nine members

REPLIGEN CORP

Pax elected to board effective March 18, 2024; board expands from eight to nine members.
Pax brings 25+ years in life sciences, including Thermo Fisher VP Strategy and Innovation (2016-2020).
Pax received initial option valued at $215,000 vesting over three years, plus pro-rata equity awards.
Pax is independent under Nasdaq standards; no committee assignments yet.
Pax also serves on boards of Alimera Sciences, Jellagen, and BioPorto U.S. subsidiary.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Margaret A. Pax

Director

RGEN · REPLIGEN CORP

Effective: 2024-03-18
Filed: March 19, 2024, 7:59 PM ET

the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Margaret A. Pax was elected as Director at REPLIGEN CORP.

Action: elected
Role: Director

Exact text from the filing

the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).

View on SEC.gov

REPLIGEN CORP filing history →

Source: SEC EDGAR

accession 0001193125-24-070768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.